Last checked at 
LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC on Monday said it has extended its existing research collaboration with Australia-based Benitec Biopharma following positive results from early studies conducted by the pair.
Researchers at ReNeuron and Benitec, which focuses on gene silencing therapeutics, have discovered that ReNeuron's CTX-derived exosomes are potentially an effective delivery system for Benitec's proprietary ddRNAi gene silencing technology, resulting in the silencing of specific genes in recipient cells to beneficial therapeutic effect, ReNeuron said.
"We are increasingly excited by the potential of our exosome platform, most particularly as a potential new therapeutic approach targeting cancer. The early data we have generated indicates that our CTX-derived exosomes may become a valuable new pipeline of cancer therapeutic candidates," said Olav Hellebø, ReNeuron's chief executive.
Shares in ReNeuron were up 4.4% to 5.35 pence in early trade on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
